Ström, O <br/><br/>
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.  [electronic resource] 

 -  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA  Apr 2013 
 - 1491-502 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1433-2965 
<br/><br/><label>Standard No.: </label>10.1007/s00198-012-2115-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Alendronate--economics<br/>Algorithms<br/>Antibodies, Monoclonal, Humanized--economics<br/>Bone Density Conservation Agents--economics<br/>Cost-Benefit Analysis<br/>Denosumab<br/>Drug Costs--statistics & numerical data<br/>Etidronic Acid--analogs & derivatives<br/>Female<br/>Health Care Costs--statistics & numerical data<br/>Humans<br/>Middle Aged<br/>Models, Econometric<br/>Osteoporosis, Postmenopausal--drug therapy<br/>Osteoporotic Fractures--economics<br/>Quality of Life<br/>RANK Ligand--antagonists & inhibitors<br/>Risedronic Acid<br/>Risk Assessment--methods<br/>Thiophenes--economics<br/>United Kingdom--epidemiology